Song Gao
Tianjin Medical University Cancer Institute and Hospital · Shengjing Hospital · Shanghai 10th People's Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Song Gao as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:47 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07436741 · Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic CancerTianjin Medical University Cancer Institute and Hospital · recruiting · Pancreatic Cancer, Adult · principal investigator
- Ph3NCT06333821 · A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical CarcinomaBiotech Pharmaceutical Co., Ltd. · not yet recruiting · Cervical Cancer · study chair
- Ph2NCT05908747 · Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic CancerTianjin Medical University Cancer Institute and Hospital · completed · Pancreatic Cancer · principal investigator
- Ph1/Ph2NCT03615313 · PD-1 Antibody Expressing mesoCAR-T Cells for Mesothelin Positive Advanced Solid TumorShanghai Cell Therapy Research Institute · unknown · Advanced Solid Tumor · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 15 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:47 UTC. The ranking covers the 200 most relevant of 378 PubMed records, and a shared surname and initials can bring in a namesake. All 378 on PubMed
- Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.N Engl J Med · 20231,104 citationsRCR 94.7
- Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.N Engl J Med · 2023770 citationsRCR 62.8
- 689 citationsRCR 34.6
- 414 citationsRCR 25.9
- A safe and potent anti-CD19 CAR T cell therapy.Nat Med · 2019368 citationsRCR 11.8
- Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.Nat Med · 2023357 citationsRCR 30.6
- Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC.J Thorac Oncol · 2020356 citationsRCR 12.7
- Design and implementation of a brain-computer interface with high transfer rates.IEEE Trans Biomed Eng · 2002346 citationsRCR 11.3
- 320 citationsRCR 34.5
- Antidepressant effect on connectivity of the mood-regulating circuit: an FMRI study.Neuropsychopharmacology · 2005249 citationsRCR 6.6